Rigel Pharmaceuticals, Inc.(NASDAQ : RIGL)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.60%||163.54||0.7%||$1305.95m|
|LLY||Eli Lilly & Co.||-1.93%||323.65||1.1%||$1056.02m|
|BMY||Bristol-Myers Squibb Co.||-0.82%||71.12||1.0%||$763.08m|
|MRK||Merck & Co., Inc.||-0.52%||86.19||0.7%||$687.90m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-4.41%||200.16||8.2%||$210.64m|
|GBT||Global Blood Therapeutics, Inc.||0.04%||68.10||5.4%||$190.73m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.21%||151.22||0.0%||$178.64m|
|IDXX||IDEXX Laboratories, Inc.||-1.81%||325.80||3.9%||$175.84m|
|HZNP||Horizon Therapeutics Plc||-1.28%||61.89||5.4%||$160.55m|
|NVO||Novo Nordisk A/S||-0.74%||99.65||0.1%||$140.44m|
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.